1. Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
- Author
-
Li, Ziming, Dang, Xiaomin, Huang, Dingzhi, Jin, Shi, Li, Weiwei, Shi, Jianhua, Wang, Xicheng, Zhang, Yiping, Song, Zhengbo, Zhang, Junping, Zhuang, Wu, Liu, Xuewen, Jiang, Liyan, Meng, Xiangjiao, Zhao, Mingfang, Zhou, Jianying, Zhang, Liangming, Wang, Pingli, Luo, Hui, Yang, Junquan, Cang, Shundong, Wang, Xiang, Zhang, Ling, Lu, Shun, Li, Ziming, Dang, Xiaomin, Huang, Dingzhi, Jin, Shi, Li, Weiwei, Shi, Jianhua, Wang, Xicheng, Zhang, Yiping, Song, Zhengbo, Zhang, Junping, Zhuang, Wu, Liu, Xuewen, Jiang, Liyan, Meng, Xiangjiao, Zhao, Mingfang, Zhou, Jianying, Zhang, Liangming, Wang, Pingli, Luo, Hui, Yang, Junquan, Cang, Shundong, Wang, Xiang, Wang, Jing, Cui, Jiuwei, Yu, Yan, Zhang, Zhihong, Lu, Junguo, Yang, Weihua, Li, Gaofeng, Feng, Jifeng, Lv, Dongqing, Wu, Lin, Fang, Yong, Wang, Yan, Zhao, Yanqiu, Cao, Baoshan, Zhu, Wei, Zhuang, Zhixiang, Li, Qingshan, Wang, Mingxi, Zhou, Huan, Dong, Xiaorong, Hu, Sheng, Fang, Jian, Xu, Chun-Wei, Zhang, Yihong, Wang, Wenjia, Xiang, Ziyong, Shi, Zhe, Wang, Yaolin, Zhang, Ling, and Lu, Shun
- Abstract
Garsorasib (D-1553; InventisBio, Shangai, China), a potent KRASG12Cinhibitor, has shown promising antitumour activity in patients with KRASG12C-mutated (ie, Gly12Cys) non-small-cell lung cancer (NSCLC) in a phase 1 study. We report results from a phase 2 study conducted to evaluate the efficacy and safety of garsorasib in patients with locally advanced or metastatic KRASG12C-mutated NSCLC.
- Published
- 2024
- Full Text
- View/download PDF